{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inhibition&page=11",
    "query": {
      "condition": "Inhibition",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 997,
    "total_pages": 100,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inhibition&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inhibition&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T07:12:36.083Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00072111",
      "title": "Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 Gene",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "anakinra",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2003-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-04-30",
      "last_synced_at": "2026-10-19T07:12:36.083Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00072111"
    },
    {
      "nct_id": "NCT04286607",
      "title": "Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Topical roflumilast",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arcutis Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "2 Years to 11 Years"
      },
      "enrollment_count": 337,
      "start_date": "2020-02-12",
      "completion_date": "2024-01-22",
      "has_results": true,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-19T07:12:36.083Z",
      "location_count": 68,
      "location_summary": "Scottsdale, Arizona • Beverly Hills, California • Encinitas, California + 58 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04286607"
    },
    {
      "nct_id": "NCT01678209",
      "title": "Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder",
        "ADHD"
      ],
      "interventions": [
        {
          "name": "fMRI scans",
          "type": "OTHER"
        },
        {
          "name": "Atomoxetine arm",
          "type": "DRUG"
        },
        {
          "name": "Methylphenidate arm",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Years to 17 Years"
      },
      "enrollment_count": 127,
      "start_date": "2012-10",
      "completion_date": "2018-04-30",
      "has_results": true,
      "last_update_posted_date": "2020-07-24",
      "last_synced_at": "2026-10-19T07:12:36.083Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01678209"
    },
    {
      "nct_id": "NCT02806414",
      "title": "Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Rosacea"
      ],
      "interventions": [
        {
          "name": "Ivermectin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 25,
      "start_date": "2016-07",
      "completion_date": "2021-05",
      "has_results": true,
      "last_update_posted_date": "2021-10-05",
      "last_synced_at": "2026-10-19T07:12:36.083Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02806414"
    },
    {
      "nct_id": "NCT04949113",
      "title": "Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Malignant Melanoma Stage III"
      ],
      "interventions": [
        {
          "name": "Neoadjuvant ipilimumab + nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Adjuvant nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Netherlands Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 423,
      "start_date": "2021-07-08",
      "completion_date": "2028-12-19",
      "has_results": false,
      "last_update_posted_date": "2024-03-08",
      "last_synced_at": "2026-10-19T07:12:36.083Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Houston, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04949113"
    },
    {
      "nct_id": "NCT00530413",
      "title": "Study of Phenobarbital Inhibition of Catamenial Epilepsy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Phenobarbital",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Toledo Health Science Campus",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2007-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-12-10",
      "last_synced_at": "2026-10-19T07:12:36.083Z",
      "location_count": 1,
      "location_summary": "Toledo, Ohio",
      "locations": [
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00530413"
    },
    {
      "nct_id": "NCT04005690",
      "title": "Targeted Pathway Inhibition in Patients With Pancreatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Locally Advanced Pancreatic Ductal Adenocarcinoma",
        "Metastatic Pancreatic Ductal Adenocarcinoma",
        "Stage II Pancreatic Cancer AJCC v8",
        "Stage III Pancreatic Cancer AJCC v8",
        "Stage IV Pancreatic Cancer AJCC v8",
        "Unresectable Pancreatic Ductal Adenocarcinoma",
        "Borderline Resectable Pancreatic Ductal Adenocarcinoma",
        "Resectable Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Onvansertib",
          "type": "DRUG"
        },
        {
          "name": "Azenosertib",
          "type": "DRUG"
        },
        {
          "name": "Saruparib",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2019-08-01",
      "completion_date": "2028-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-10-19T07:12:36.083Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04005690"
    },
    {
      "nct_id": "NCT05670782",
      "title": "A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's Disease",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "KM-819",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "FAScinate Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 314,
      "start_date": "2022-07-19",
      "completion_date": "2025-11-13",
      "has_results": false,
      "last_update_posted_date": "2025-03-05",
      "last_synced_at": "2026-10-19T07:12:36.083Z",
      "location_count": 3,
      "location_summary": "Glendale, California • San Diego, California • Royal Oak, Michigan",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05670782"
    },
    {
      "nct_id": "NCT00585559",
      "title": "Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Aneurysmal Subarachnoid Hemorrhage",
        "Cerebral Vasospasm"
      ],
      "interventions": [
        {
          "name": "Placebos for acetaminophen and N-acetylcysteine",
          "type": "DRUG"
        },
        {
          "name": "APAP 1 gm every 6 hours and N-acetylcysteine placebo",
          "type": "DRUG"
        },
        {
          "name": "NAC IV infusion at 0.5 gm hourly and APAP placebo",
          "type": "DRUG"
        },
        {
          "name": "APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly",
          "type": "DRUG"
        },
        {
          "name": "APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2007-04",
      "completion_date": "2023-10-26",
      "has_results": true,
      "last_update_posted_date": "2025-04-18",
      "last_synced_at": "2026-10-19T07:12:36.083Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00585559"
    },
    {
      "nct_id": "NCT01701973",
      "title": "Effect of DPP4 Inhibition on Growth Hormone Secretion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "Pegvisomant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "L-NMMA",
          "type": "DRUG"
        },
        {
          "name": "Exendin 9-39",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 44,
      "start_date": "2013-01",
      "completion_date": "2017-05",
      "has_results": true,
      "last_update_posted_date": "2018-05-29",
      "last_synced_at": "2026-10-19T07:12:36.083Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01701973"
    }
  ]
}